[Corrigendum] Human chorionic gonadotropin β regulates epithelial‑mesenchymal transition and metastasis in human ovarian cancer

Na Liu, Shumin Peng, Guangxi Zhan, Jing Yu, Weimin Wu, Hao Gao, Xiaofeng Li, Xiaoqing GuoOncology 2025 · DOI · OpenAlex

Human Chorionic Gonadotropin β Regulates EMT and Metastasis in Ovarian Cancer: A Corrigendum and Review

Abstract

This paper reviews the role of Human Chorionic Gonadotropin β (β-hCG) in driving the progression of human ovarian cancer through the regulation of Epithelial-Mesenchymal Transition (EMT). While originally published in 2017, several figure assembly errors were recently identified and corrected via a formal corrigendum. This review incorporates those corrections, reaffirming that β-hCG acts as a critical oncogenic signal that enhances the migratory and invasive capabilities of ovarian cancer cells.

Introduction

Ovarian cancer remains a significant clinical challenge due to its high metastatic potential. A key driver of this metastasis is Epithelial-Mesenchymal Transition (EMT), a process where stationary epithelial cells transform into mobile mesenchymal cells. The 2017 study by the research team identified β-hCG, a hormone typically associated with pregnancy, as a potent regulator of this transition in ovarian cancer cell lines. Following post-publication review, errors in Figures 2, 3, and 6 were identified, involving duplicate panels and overlapping western blot data. This document presents the corrected findings, ensuring the scientific record accurately reflects the study's valid conclusions.

Methods

The researchers utilized two human ovarian cancer cell lines, ES-2 and SKOV3, to model the disease. To investigate the function of β-hCG, they employed genetic manipulation techniques:

  • Overexpression: Lentiviral (LV) vectors were used to increase β-hCG expression.
  • Knockdown: Small interfering RNA (siRNA) was used to "silence" or knock down β-hCG expression.

The efficacy of these manipulations was verified using RT-PCR for mRNA levels and Western blotting for protein levels. Functional consequences were assessed via scratch-wound assays to measure cell migration, while the molecular mechanisms were explored by quantifying EMT markers such as Slug, β-catenin, Vimentin, and E-cadherin.

Key Results

The core findings of the study demonstrate that β-hCG levels directly correlate with the metastatic phenotype of ovarian cancer cells.

Validation of β-hCG overexpression (B) and knockdown (C) in ES-2 and SKOV3 cell lines.

As shown in the corrected Figure 2, the researchers successfully established models of β-hCG overexpression and knockdown. In the overexpression models (LV-β-hCG), cells exhibited significantly increased migratory capacity in scratch-wound assays. Conversely, silencing β-hCG (siRNA-β-hCG) inhibited migration.

Molecular analysis confirmed that β-hCG drives EMT by modulating master regulators like Slug and β-catenin. High levels of β-hCG led to the downregulation of the epithelial marker E-cadherin and the upregulation of mesenchymal markers like Vimentin. The corrected Figure 6 specifically clarifies the protein expression patterns of these markers, confirming that β-hCG silencing can effectively reverse the EMT phenotype.

Discussion and Conclusion

The correction of the original figures does not alter the fundamental conclusions of the research. β-hCG is a significant driver of metastasis in ovarian cancer by promoting EMT. The study highlights the potential of β-hCG as a therapeutic target; inhibiting its signaling pathway could provide a means to limit the spread of aggressive ovarian tumors. Furthermore, this corrigendum underscores the importance of scientific transparency and the self-correcting nature of the peer-review process, ensuring that the foundation for future clinical applications remains robust.

Future research should focus on in vivo validation of these findings and exploring the potential crosstalk between β-hCG and other major oncogenic pathways, such as Wnt/β-catenin or TGF-β.

Summary updated

Abstract

Following the publication of the above article, an interested reader drew to the Editor's attention that, for the scratch‑wound assay experiments shown in Fig. 3 on p. 1468, the "ES‑2 LV‑β‑hCG" and "ES‑2 siRNA‑β‑hCG" data panels were apparently the same, suggesting that the same data panel had erroneously been included twice in this figure. Furthermore, β‑actin blots featured in Fig. 2C on p. 1467, and certain of the western blot data featured in Fig. 6A on p. 1470, were strikingly similar to western blot data that appeared in papers subsequently published by the same research group in the journals <i>Cell Cycle</i> and <i>Cancer Science</i>, respectively; finally, the same western blot data had been selected to represent β‑catenin and Slug protein bands in Fig. 6A. After having examined their original data, the authors realized that these figures had been inadvertently assembled incorrectly. The revised versions of Fig. 2 (showing all the correct β‑actin data in Fig. 2C), Fig. 3 (showing the correct data for the "ES‑2 siRNA‑β‑hCG" experiment) and Fig. 6 (showing the correct data for the "Slug/ES‑2 siRNA‑β‑hCG" and "Slug/SKOV3 siRNA‑β‑hCG" protein bands) are shown on the next two pages. Note that the revisions made to these figures do not affect the overall results and conclusions reported in the paper. The authors are grateful to the Editor of <i>Oncology Reports</i> for granting them the opportunity to publish this corrigendum, and all the authors agree with its publication; furthermore, they apologize to the readership of the journal for any inconvenience caused. [Oncology Reports 38: 1464‑1472, 2017; DOI: 10.3892/or.2017.5818].
BibTeX
@inproceedings{liu2025corrigendum,
  author = {Na Liu and Shumin Peng and Guangxi Zhan and Jing Yu and Weimin Wu and Hao Gao and Xiaofeng Li and Xiaoqing Guo},
  title = {{[Corrigendum] Human chorionic gonadotropin β regulates epithelial‑mesenchymal transition and metastasis in human ovarian cancer}},
  booktitle = {Oncology},
  year = {2025},
  doi = {10.3892/or.2025.8948},
}
Figure